These findings corroborate previous BCP-ALL studies (AIEOP-BFM 2000, St Jude and COG, DCOG ALL-10) that reported high CRLF2 mRNA expression in 5-7% ALL patients [12–15]. This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.